Intellia Therapeutics, Inc 10-Q for FY2026 Q3
Intellia Therapeutics, Inc. (NTLA)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
Intellia Therapeutics, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Intellia Therapeutics said the FDA accepted lonvo-z’s BLA, granted Priority Review and set a March 10, 2027 target action date, supporting a planned first quarter 2027 U.S. launch if approved. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $7.16M
- down 48.0% from $13.78M a year earlier
- Net loss
- $127.49M
- compared with a net loss of $101.32M a year earlier
- Diluted EPS
- -$0.91
- compared with -$0.92 a year earlier